Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake
Executive Summary
The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.
You may also be interested in...
Relmada Hopes Open-Label Efficacy, Safety Bolster Profile Of Depression Candidate
With a pair of Phase III setbacks due to high placebo response, Relmada reports positive efficacy and safety data from an open-label trial while awaiting data from two ongoing pivotal studies for REL-1017, an NMDA antagonist.
J&J Hedges On 2025 Pharma Revenue Outlook
The company admitted it may not meet a goal set in 2021 to reach a $60bn pharmaceutical revenue target in 2025.
Janssen Secures Only Partial Win In Appeal Against English Funding Snub For Spravato
Of the nine specific appeal points raised against NICE’s rejection of the company’s antidepressant nasal spray, Spravato, just one was upheld.